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Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, GermanyIntroduction: Chronic kidney disease (CKD) engenders salt-sensitive hypertension. Whether or not tissue
Naþ accumulation is increased in CKD patients remains uncertain. How tissue Naþ is affected after renal
transplantation has not been assessed.
Methods: We measured tissue Naþ amount in 31 CKD patients (stage 5) and prospectively evaluated
tissue Naþ content at 3 and 6 months, following living-donor kidney transplantation. Additionally, pre- and
post-transplantation data were compared to 31 age- and sex-matched control subjects. 23Na–magnetic
resonance imaging (23Na-MRI) was used to quantify muscle and skin Naþ of the lower leg and water
distribution was assessed by bioimpedance spectroscopy.
Results: Compared to control subjects, CKD patients showed increased muscle (20.7  5.0 vs. 15.5  1.8
arbitrary units [a.u.], P < 0.001) and skin Naþ content (21.4  7.7 vs. 15.0  2.3 a.u., P < 0.001), whereas
plasma Naþ concentration did not differ between groups. Restoration of kidney function by successful
renal transplantation was accompanied by mobilization of tissue Naþ from muscle (20.7  5.0 vs. 16.8  2.8
a.u., P < 0.001) and skin tissue (21.4  7.7 vs. 16.8  5.2 a.u., P < 0.001). The reduction of tissue Naþ after
transplantation was associated with improved renal function, normalization of blood pressure as well as an
increase in lymphatic growth-factor concentration (vascular endothelial growth factor C [VEGF-C] 4.5  1.8
vs. 6.7  2.7 ng/ml, P < 0.01).
Conclusions: Tissue Naþ accumulation in predialysis patients with CKD was almost completely reversed to
the level of healthy controls after successful kidney transplantation.
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KD is a major public health care burden as the
prevalence is high, particularly within aging so-
cieties.1,2 Hypertension is one of the primary risk fac-
tors for cardiovascular disease, the main cause of
morbidity and mortality in CKD patients.3 Salt (NaCl)
intake is said to be largely responsible for hypertension
in CKD patients and guidelines recommend salt re-
striction to ameliorate renal function loss and target-spondence: Christoph Kopp, Department of Nephrology and
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ne 2021organ damage.4 Recent findings indicate that Naþ can
accumulate and be stored at the tissue level bound to
glycosaminoglycans.5,6 Tissue Naþ deposition might be
a relevant mechanism of Naþ-homeostasis alongside
adjustments to extracellular fluid expansion in CKD
patients. Previously, we introduced 23Na-MRI at our
facility to visualize and quantify tissue Naþ non-
invasively.7 We found that primary and secondary
hypertension are accompanied by pronounced tissue
Naþ retention, and that treatment of hyperaldosteronism
is able to reverse this pathological condition.8 Further-
more, skin Naþ content in patients with mild to mod-
erate CKD was the best predictor for left ventricular
hypertrophy, indicating a close relationship betweenKidney International Reports (2021) 6, 2338–2347
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þ After Renal Transplantation CLINICAL RESEARCHtissue Naþ deposition and target-organ damage.9 Tissue
Naþ accumulation occurs in maintenance hemodialysis
(HD) and peritoneal dialysis patients.10 HD patients with
type 2 diabetes mellitus who are at a particularly high
risk for cardiovascular disease have higher tissue Naþ
content compared to nondiabetic HD patients.11
Removal of tissue Naþ in HD patients during a regular
4-hour dialysis treatment is independent of dialysis ul-
trafiltration, whereas the concentration of VEGF-C, a
lymphatic growth factor, correlates with skin Naþ
mobilization in these patients. VEGF-C is suppressed in
HD patients while in parallel, soluble vascular endo-
thelia growth factor receptor 3 (sVEGFR3) — a trap for
VEGF-C— is increased.12 These findings are in line with
previous preclinical studies showing that the lymphatic
system plays an important role in tissue electrolyte
clearance and blood pressure regulation.6,13,14
In contrast to HD patients, data on tissue Naþ
deposition in patients with severe CKD are limited and
show conflicting results.15,16 Furthermore, whether the
restoration of renal function by kidney transplantation
is associated with a normalization of tissue Naþ amount
is not known. We hypothesized that tissue Naþ accu-
mulation occurring in predialysis CKD patients would
be reduced within 6 months after successful living-
donor kidney transplantation. In addition, we investi-
gated potential underlying mechanisms of this tissue
Naþ mobilization.METHODS
Study Population
The local ethics Committee of the University of Erlan-
gen–Nürnberg, Germany (No. 3948 and 271_17B)
approved the study, which was conducted according
to the Declaration of Helsinki. All study participants
provided written informed consent and were assessed
at our clinical research facility at the University Hos-
pital Erlangen. Patients were recruited from our
transplantation center and our outpatient clinic. Pa-
tients with stable CKD stage 5 (estimated glomerular
filtration rate < 15 ml/min per 1.73 m2) scheduled for
pre-emptive living-donor transplantation were
included in our prospective cohort study. None of the
participants has been on dialysis treatment before the
first 23Na-MRI assessment. Twenty-eight patients
received pre-emptive living-donor transplantation;
however, 3 patients required short-term HD treatment
before transplantation. The study sample size was
determined using G*Power software for power analyses
of t test.17 With 0.80 power, adjusted type I error test
at level 5%, and an expected reduction of tissue Naþ of
5.2  6.2 a.u. after intervention as found in our pre-
vious dialysis study, a minimum of 14 subjects perKidney International Reports (2021) 6, 2338–2347group were necessary.12 Exclusion criteria were pa-
tients with implanted metal, pregnant women, body
mass index $ 40 kg/m2, malignant disease within the
last 2 years, autoimmune disease, acute infection, sur-
gery within the last 3 months, liver cirrhosis (Child C),
congestive heart failure (New York Heart Association
functional class IV), and patients meeting acute dialysis
criteria. Diagnoses were obtained from medical reports.
Patients were compared to age- and sex-matched
healthy control subjects. Control subjects were
recruited by newspaper advertisement. Recruitment of
all study participants took place between January 2012
and November 2017. Healthy controls did not receive
regular medication, except for L-thyroxine (two sub-
jects), a contraceptive tablet (one subject), and glau-
coma eye drops (one subject). Blood pressure of control
subjects had to be within the normal range (<140/90
mm Hg) as defined by European Society of Hyperten-
sion/European Society of Cardiology. Participants un-
derwent a blood and urine laboratory workup
(including 24-hour urine samples) and were assessed
for their medical history. Before MRI examination,
blood pressure was measured after 5 minutes of rest in
seated position using an automated oscillometric device
(Dinamap, Critikon, Carlsbad, California, USA). Before
recording, blood pressure was analyzed on both upper
arms and the arm with higher pressure was chosen.
Three consecutive measurements were averaged.
CKD patients were followed in a prospective cohort
study. Follow-up examinations of tissue Naþ and
clinical parameters were performed 3 and 6 months
after transplantation and medical history after trans-
plantation was assessed by questionnaire and medical
reports. Follow-up ended on May 2018. The detailed
immunosuppressive regime of the kidney transplant
patients is depicted in Table 1.Bioimpedance Spectroscopy
To determine the fluid status of the study participants,
a bioimpedance device was used (Body Composition
Monitor, Fresenius Medical Care, Bad Homburg, Ger-
many). Electrodes were attached to the hand and the
foot of the ipsilateral side of the patient and impedance
spectroscopy was measured with frequencies reaching
from 5 kHz to 1 MHz. While high frequencies pass
through the whole-body water, very low frequencies
are not able to penetrate cell membranes; thus, they
only pass through the extracellular water (ECW) space.
The generated impedance data are applied to calculate
total body water, intracellular water, and ECW using
the model proposed by Chamney et al.18 Additionally,
the individual excess in ECW (overhydration), cor-
recting for sex, age, and body mass was calculated.2339
Table 1. Clinical characteristics of chronic kidney disease patients pre– and 3 to 6 months post– renal transplantation and control subjectsa
Characteristics
CKD 3 Months After Transplantation 6 Months After Transplantation Controls
(n [ 31) (n [ 29) (n [ 31) (n [ 31)
Demographics
Women/men, n 9/22 8/21 9/22 9/22
Age, y 48.0  13.2 — — 48.2  13.6
eGFR (CKD-EPI), ml/min 9  3 52  12d 53  14d 95  13b,c
Body mass index, kg/m2 25.8  3.8 25.7  3.7 25.9  3.8 24.1  3.4
Body weight, kg 79.9  18.1 79.9  17.4 79.5  18.0 75.4  11.8
Systolic BP, mm Hg 140  15 121  14d 123  13d 118  12b
Diastolic BP, mmHg 87  9 79  9d 78  9d 74  8b
MAP, mm Hg 105  10 92  11d 93  10d 89  8b
Pulse pressure, mm Hg 53  11 42  8d 45  11d 44  10b
Comorbidities
Hypertension 31 28 26 0
BP medication 3.0  1.5 2.6  1.2 2.0  1.3d —
Atrial fibrillation 1 2 2 0
Congestive heart failure 1 1 1 0
Coronary artery disease 0 0 0 0
Diabetes mellitus 2 2 2 0
Post-transplant diabetes — 4 1 —
BIS data
Total body water, liter 43.2  9.1 40.5  8.2d 40.7  8.2d 40.6  6.6
ECW, l 19.7  4.4 18.5  4.2d 18.5  4.0d 17.7  2.4b
ICW, l 23.5  5.0 22.0  4.2d 22.2  4.4d 22.9  4.2
Ratio ECW/ICW 0.84  0.09 0.84  0.07 0.84  0.09 0.78  0.06b,c
Biochemistry serum
Potassium, mmol/l 4.7  0.4 4.2  0.5d 4.1  0.4d 4.0  0.3b
Creatinine, mg/dl 7.1  2.2 1.5  0.2d 1.5  0.4d 0.9  1.1b,c
hs CRP, mg/dl 3.3  3.8 4.9  14.5 7.4  19.0 1.7  2.0b
Glucose, mg/dl 104  30 109  15d 112  24 98  19c
HbA1c, % 5.3  0.5 6.0  0.8d 5.7  0.5d 5.4  0.3
Uric acid, mg/dl 7.4  1.7 6.6  1.7 6.8  1.4 5.0  1.2b,c
Lactate, mg/dl 0.9  0.4 1.2  0.4d 1.2  0.4d 1.5  1.3b
Triglyceride, mg/dl 198  99 204  83 199  96 120  77bc
Cholesterol, mg/dl 209  46 204  50 202  55 203  40
LDL, mg/dl 141  38 131  39 127  40 125  32b
Aldosterone, ng/ml 0.21  0.16 0.08  0.05d 0.10  0.25d 0.10  0.06b
Biochemistry urine
Urine Naþ, mmol/24 h 204  86 195  95 179  82 187  78
UACR, mg/g creatinine 2409  1977 66  73d 48  59d 18  26b
U-osmolality, mosm/kg 285  53 319  110 319  111 459  169b,c
aVariables are presented as mean  standard deviation.
bP(Control vs. CKD) < 0.05.
cP(Control vs. RT 6 mo) < 0.05.
dP(RT vs. CKD) < 0.05.
BIS, bioimpedance spectroscopy; BP, blood pressure; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; ECW, extracellular water; eGFR,
estimated glomerular filtration rate; HbA1c, glycated hemoglobin; hs CRP, high-sensitivity C-reactive protein; ICW, intracellular water; LDL, low-density lipoprotein; MAP, mean arterial
pressure; RT, renal transplantation; UACR, urine albumin-to-creatinine ratio.
CLINICAL RESEARCH A Dahlmann et al.: Tissue Naþ After Renal TransplantationTissue Naþ assessment by 23Na-MRI
We applied 23Na-MRI to quantify tissue Naþ in human
skin and muscle as described previously.8,12 We
measured tissue Naþ content in the region of the dorsal
lower leg (at the largest circumference) with a 23Na
volume coil (Stark-Contrast, Erlangen, Germany) and a
3.0 Tesla magnetic resonance imaging scanner (Mag-
netom Verio or Magnetom Skyra, Siemens Healthcare,
Erlangen, Germany). For analysis, the left lower leg was
placed on a cylindrical-shaped surface to avoid devia-
tion in the Z-axis. We used a two-dimensional fast low2340angle shot sequence (total acquisition time ¼13.7 mi-
nutes, echo time ¼ 2.07 ms, repetition time ¼ 100 ms,
flip angle ¼ 90, 128 averages, resolution: 3  3  30
mm3). Four tubes containing aqueous solutions with 10,
20, 30, and 40 mmol/l NaCl served as calibration stan-
dards by relating intensity to a concentration in a
linear trend analysis. The low in-plane resolution re-
sults in partial volume effects; thus, giving an under-
estimation of the Naþ skin content because the skin
thickness is approximately 1 mm. In addition, the Naþ
concentration of subcutaneous fat tissue influences theKidney International Reports (2021) 6, 2338–2347
Table 2. Underlying nephropathy and medication list of all 31 CKD











Diabetic nephropathy 1 — —
ADPKD 8 — —
Primary FSGS 4 — —
IgA nephritis 7 — —




Unknown 2 — —
Medication
Immunosuppression 1 29 31
Tacrolimus 0 25 27




Belatacept 0 1 1
Sirolimus 0 0 2
Azathioprine 0 0 1
Prednisolone 1 29 31




ARB 13 16 10
ACEi 6 7 8
Diuretics 14 2 3
Calcium antagonist 19 16 10




Others 15 9 7
Bicarbonate 24 4 0
Statins 15 29 27





ADPKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease;
FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgA, immunoglobulin
A; IQR, interquartile range.
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þ After Renal Transplantation CLINICAL RESEARCHmeasured skin Naþ, and the fast decay of the 23Na-MRI
signal can result in an underestimation of tissue Naþ
amount. To account for these limitations, we labeled
the tissue Naþ concentration obtained by the calibra-
tion as arbitrary units (a.u.). For the entire study, the
compartments of the lower leg, namely, triceps surae
muscle and cutis were identified by the same experi-
enced physicist. The anatomical regions of interest
were drawn guided by the anatomical image (T1-
weighted fast low angle shot sequence). The skin of
the dorsal lower leg located directly above the
cylindrical-shaped surface of the calibration tube
holder was used for Naþ assessment. In the Naþ image,
a threshold of twice the background noise defined the
border for pixels that were included in skin Naþ
calculation. Examples of our Naþ image analysis can be
found in a previous publication.19
Statistical Analysis
We used the SPSS software (version 24.0, IBM,
Armonk, New York, USA). Original output data and
Syntax files used for analysis will be provided on
request. P < 0.05 was considered significant and two-
sided tests of hypotheses were used throughout. Group
differences between patients and controls were tested
using the Student t test with adjustment for unequal
variance as needed, or the Wilcoxon rank sum test.
Intraindividual differences of transplant recipients
were tested with the paired t test or the Wilcoxon
signed rank test where appropriate. Differences in
proportions were assessed using the chi square test.
Clinical, laboratory, and metabolic parameters were
used in a univariate analysis to study associations with
skin Naþ and muscle Naþ. Because there were three
measurements over time, a generalized estimating
equation was used. Generalized estimating equation
adjusts for intrasubject correlation and facilitates
implementation of the Markov correlation structure,
which is appropriate for modeling associations among
measurements that are unequally spaced in time.
RESULTS
In the present study, 31 patients with CKD stage 5
underwent living-donor kidney transplantation and
were prospectively assessed prior, and at 3 and 6
months after surgery (on average 3.1  0.5 and 6.2 
0.4 months) to detect changes in tissue Naþ content
after restored kidney function. Additionally, CKD pa-
tients were compared to 31 age- and sex-matched
healthy control subjects. In our cohort, 28 patients
received a pre-emptive transplantation and 3 patients
required short-term HD before transplantation. None of
the patients has been on dialysis treatment before the
first 23Na-MRI measurement. Anthropometric data,Kidney International Reports (2021) 6, 2338–2347comorbidities, and biochemistry including metabolic
parameters of study participants are outlined in
Table 2. Specific medication and underlying renal dis-
eases are presented in Table 1. After renal trans-
plantation, serum creatinine levels decreased in CKD
patients from 7.09  2.18 to 1.51  0.24 mg/dl after 3
months, and were 1.51  0.36 mg/dl after 6 months,
whereas estimated glomerular filtration rate increased
accordingly. No graft loss occurred. Blood pressure
values as well as burden of antihypertensive medica-
tion were significantly reduced after transplantation.
Representative 23Na-MRIs of a CKD patient pre-
surgery, 3 and 6 months post-surgery as well as a
corresponding healthy control subject are depicted in2341








Male 30 y/o paent
Muscle 21.0











Male 33 y/o subject
Control
Skin 10.9
Figure 1. Representative 23Na–magnetic resonance images (23Na-MRIs) of a chronic kidney disease (CKD) patient (pre– and post–renal
transplantation), and its age-matched control person. Upper panel shows 23Na-MRI of the left lower leg of a 30-year-old man with CKD
stage 5 before (left image) as well as 3 months (middle image) and 6 months (right image) after pre-emptive living-donor kidney transplantation.
Calibration tubes with 10, 20, 30, and 40 mmol/l are placed below the left lower leg. The brightness of the Naþ resonance signal in muscle and
skin tissue is markedly reduced following renal transplantation — reaching signal intensities close to the 23Na-MRI of a 33-year-old healthy
control man (see boxed images, lower panel).
CLINICAL RESEARCH A Dahlmann et al.: Tissue Naþ After Renal TransplantationFigure 1, indicating decreased tissue Naþ signaling af-
ter transplantation. Paired data from all 31 CKD patients
show significant reduction of tissue Naþ content in
muscle and skin after renal replacement therapy
(Figure 2a and b). We note that the actual tissue Naþ
content is underestimated by the methodology (see
Methods section). Detailed assessment revealed a signifi-
cant reduction of mean tissue Naþ content already 3
months after transplantation (20.7  5.0 vs. 16.8  3.0
a.u., P< 0.001 muscle and 21.4 7.7 vs. 16.5 4.7 a.u.,
P < 0.001 skin), which persisted on follow-up examina-
tion after 6months (16.9 2.8 a.u.,P< 0.001,muscle and
16.7  5.3 a.u., P < 0.001, skin) (Figure 2c and d, indi-
vidual tissueNaþdata are depicted in Supplemental Table
S1). Compared to age- and sex-matched healthy controls
tissue, Naþ was significantly higher in CKD patients
pretransplantation (skin21.4 7.7vs. 15.0 2.3 a.u.,P<
0.001, muscle 20.7  5.0 vs. 15.5  1.8 a.u., P < 0.001).
Despite the reduction, tissue Naþ did not reach the level
of control subjects 6 months after transplantation, with a
significant difference in muscle (15.5 1.8 vs. 16.8 2.8
a.u., P < 0.05) (Figure 2c), and only a tendency in skin
(skin 15.0 2.3 vs. 16.8 5.2 a.u., P¼ 0.07) (Figure 2d).
In our cohort, six acute allograft rejections were
detected histologically without a significant increase in
serum creatinine compared to patients not experiencing
rejection (no rejection 1.48  0.27 vs. rejection 1.65 
23420.65 mg/dl, P ¼ 0.55 after 6 months). No difference in
tissue Naþ amount could be detected in patients with
acute rejection compared to patients without (skin 15.6
 5.1 vs. 17.1  5.3 a.u., P ¼ 0.52; muscle 17.0  3.2
vs. 16.7  2.8 a.u., P ¼ 0.86) (Supplemental Table S2).
Further subanalysis of CKD patients with diabetes
mellitus (two patients with type 2 diabetes mellitus
plus four patients with post-transplantation diabetes)
as well as three CKD patients requiring short-term HD
before surgery are also shown in Supplemental
Table S2. No differences in tissue Naþ between dia-
betes and nondiabetes patients were observed.
There was a numerical reduction in overhydration
assessed by bioimpedance spectroscopy (BIS) over the
follow-up period; however, the significance level was not
reached (1.7 1.6 vs. 1.2 1.7 l, P¼ 0.22 after 3 months
and vs. 1.0  1.2 l, P ¼ 0.05 after 6 months) (Figure 3a).
Additionally, BIS detected excess ECW (overhydration)
in CKD patients (0.2  1.1 vs. 1.7  1.6 L, P < 0.001)
(Figure 3a), whereas total body water was not signifi-
cantly increased compared to controls, as shown in
Table 2. No differences were observed in plasma Naþ
concentration between control subjects and CKD patients
(137 2 vs. 138 3 mmol/l, P¼ 0.27) (Figure 3b) and 24-
hour urineNaþ amount (187 78 vs. 204 86mmol/24 h,
P¼ 0.46) (Table 2). The observeddifferences in tissueNaþ






































































































Figure 2. Changes in tissue Naþ content after renal transplantation (RT) and comparison to age- and sex-matched control subjects. Individual
muscle (a) and skin (b) tissue Naþ significantly decreased after renal transplantation (n ¼ 31). (c) Mean muscle Naþ content significantly
decreased 3 months after transplantation and persisted on this level (red box plots, n ¼ 29 [3 months], n ¼ 31 [6 months]). Six months after
surgery, muscle Naþ of kidney transplant recipients was still significantly higher compared to control subjects (blue box plot, n ¼ 31)). (d)Mean
skin Naþ content significantly decreased 3 months after transplantation and persisted on this level (red box plots, n ¼ 29 [3 months], n ¼ 31 [6
months]). Six months after surgery, skin Naþ of kidney transplant recipients was no longer significantly different compared to control subjects
(blue box plot, n ¼ 31). **P < 0.001. *P < 0.05. a.u., arbitrary units; MRI, magnetic resonance imaging; n.s. not significantly different.
A Dahlmann et al.: Tissue Na
þ After Renal Transplantation CLINICAL RESEARCHpatients after transplantation compared to healthy con-
trols (0.2  1.1 vs. 1.0  1.2 L, P < 0.01) (Figure 3a).
As the lymphatic system played a pivotal role in in
tissue Naþ homeostasis in previous studies, we assessed
lymphatic factors (VEGF-C and sVEGFR3) in the blood
of our CKD patients. Following 3 and 6 months after
transplantation, VEGF-C concentration significantly
increased and sVEGFR3 decreased (VEGF-C: 4.5  1.8
vs. 6.6  3.1 (3 months) vs. 6.6  2.7 ng/ml (6 months),
P < 0.01; sVEGFR3: 34.4  18.5 vs. 27.7  14.5 (3
months) vs. 26.7  16.5 ng/ml (6 months), P < 0.05)
(Figure 3c and d). Compared to age- and sex-matched
control subjects, VEGF-C concentrations in CKD patients
were significantly lower and, although increasing, did
not reach values of healthy control subjects 6 months
after kidney transplantation. No significant differences in
sVEGFR3 concentrations between CKD patients and
control subjects could be detected (Figure 3d).
To assess factors that might influence changes in tissue
Naþ after transplantation over time (including all three
study visits), we investigated correlations betweenKidney International Reports (2021) 6, 2338–2347clinical, laboratory, and metabolic parameters by using a
generalized estimating equation. We found that age,
systolic blood pressure, creatinine, and overhydration
were associatedwithmuscle Naþ accumulation. The same
correlations plus an association with gender and VEGF-C
could be found for skinNaþ content, as shown in Table 3.DISCUSSION
To date, transplantation is the best available renal
replacement therapy in end-stage renal disease due to a
higher survival rate of kidney transplant recipients
compared to patients on maintenance dialysis.20
Whether this therapy is associated with a change in
tissue Naþ content in CKD patients has not been eval-
uated before now. The main novel finding of our study
was that tissue Naþ amount in CKD patients decreased
after transplantation in muscle and skin tissue. Be-
sides this, we were able to show that patients with
pre–terminal CKD develop tissue Naþ overload

















































































































Figure 3. Changes in overhydration, plasma Naþ, and lymphangiogenic factors after renal transplantation (RT) and comparison to age and sex-
matched control subjects. (a) Overhydration did not significantly decrease after 3 months but was reduced 6 months after RT, albeit not reaching
statistical significance (red box plots, n¼ 29 [3months], n¼ 31 [6months]). In kidney transplant recipients, overhydration remained significantly higher
6months after surgery compared tocontrol subjects (bluebox plot, n¼ 31). (b)PlasmaNaþ concentrationwasunaffected byRT (red box plots, n¼ 29 [3
months], n¼ 31 [6 months]) and did not differ 6 months after surgery between kidney transplant recipients and control subjects (blue box plot, n¼ 31).
(c) Plasma vascular endothelial growth factor C (VEGF-C) concentration significantly increased 3 months after transplantation and persisted on this
level (red box plots, n¼ 31 [chronic kidney disease (CKD)], n¼ 28 [3months], n¼ 29 [6months]). Sixmonths after surgery a nonsignificant (n.s.) trend to
lower plasma VEGF-C concentrations could be found in kidney transplant recipients compared to control subjects (blue box plot, n¼ 31). (d) Plasma
soluble vascular endothelial growth factor receptor 3 (sVEGFR3) significantly decreased 3months after transplantation and persisted on this level (red
box plots, n¼ 31 (CKD), n¼ 28 [3months], n¼ 29 [6months]). Sixmonths after surgery sVEGFR3concentrations of kidney transplant recipientswere not
different compared to control subjects (blue box plot, n¼ 31). **P < 0.001. *P < 0.05. ECW, extracellular water.
CLINICAL RESEARCH A Dahlmann et al.: Tissue Naþ After Renal Transplantationsubjects. Tissue Naþ of CKD patients has been inves-
tigated by others. However, previous studies
involving 23Na-MRI found either no difference in
tissue Naþ content between CKD patients and healthy
controls or solely in the subcutaneous compartment.
The discrepancy to our data might be due to a wide
variety of CKD stages and low patient numbers in the
former and a relatively small control population in the
later study.15,16 Assessment of skin biopsy specimens
from renal transplant donors and recipients — pre-
emptive and receiving HD — did not detect signifi-
cant increased Naþ content.21 However, the examined
HD patients were assessed directly after dialysis
treatment, which might have reduced tissue Naþ ac-
cording to our 23Na-MRI study in dialysis patients.122344In our investigation, a pronounced Naþ reduction in
muscle and skin tissue could already be detected 3
months after surgery without any further significant
changes after 6 months, indicating a rapid and persis-
tent effect on tissue Naþ amount after renal trans-
plantation. When compared to age-and sex-matched
controls, Naþ was not completely normalized in muscle
tissue post-transplantation, although all 31 patients
obtained a stable kidney function throughout the end
of our observational period (estimated glomerular
filtration rate ¼ 53  14 ml/min per 1.73 m2) (Table 2).
As we performed a prospective observational study
and no randomized control trial, we were not able to
prove a causative relationship between transplantation
and tissue Naþ reduction. Multiple confounders mightKidney International Reports (2021) 6, 2338–2347
Table 3. Correlation between muscle Naþ or skin Naþ and various
anthropometric, metabolic and lymphangiogenic parameters




Coefficient P 95% Confidence Interval
Muscle Naþ
Age (per decade) 0.151 0.000 0.090 to 0.213
Sex -1.379 0.232 -3.640 to 0.882
Systolic blood pressure 0.106 0.000 0.062 to 0.149
Overhydration 1.268 0.000 0.752 to 1.783
Creatinine 0.673 0.000 0.475 to 0.871
VEGF-C -0.278 0.086 -0.595 to 0.039
sVEGFR3 0.029 0.311 -0.028 to 0.086
hs CRP 0.029 0.357 -0.033 to 0.091
HbA1c -0.606 0.390 -1.988 to 0.775
LDL-cholesterol 0.022 0.051 -0.000 to 0.043
Aldosterone 0.286 0.905 -4.396 to 4.968
Skin Naþ
Age (per decade) 0.229 0.000 0.113 to 0.345
Sex -6.036 0.001 -9.452 to -2.620
Systolic blood pressure 0.150 0.000 0.092 to 0.207
Overhydration 2.092 0.000 1.402 to 2.783
Creatinine 0.844 0.000 0.584 to 1.104
VEGF-C -0.785 0.000 -1.193 to -0.378
sVEGFR3 -0.060 0.157 -0.144 to 0.023
hs CRP -0.025 0.564 -0.110 to 0.060
HbA1c -0.483 0.638 -2.496 to 1.531
LDL-cholesterol 0.016 0.324 -0.015 to 0.047
Aldosterone 1.219 0.704 -5.076 to 7.514
hs CRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; VEGF-C,
vascular endothelia growth factor C; sVEGFR 3, soluble vascular endothelia growth
factor receptor 3.
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Particularly, initiation of immunosuppressive therapy
could have affected Naþ/water distribution. Calci-
neurin inhibitors, which were administered to the
majority (90%) of our kidney transplant recipients, are
known to affect Naþ reuptake of the kidney by acti-
vating the Naþ-Cl--cotransporter.22 Glucocorticoid
excess is able to stimulate renal Naþ reabsorption,23
whereas increased renal Naþ excretion was paralleled
by high endogenous glucocorticoid concentrations in a
human Naþ balance study.24 However, despite a sig-
nificant reduction of glucocorticoid dosage from month
3 to month 6 post-transplantation (7.5 mg, interquartile
range [IQR] 2.5 vs. 5 mg, IQR 0; P < 0.05) (Table 1), no
equivalent changes in tissue Naþ occurred. This state-
of-affairs indicates no direct correlation between tissue
Naþ content and glucocorticoid intake in our study.
Besides the immunosuppressant therapy, age, sex, and
pre-existing diseases might all have interfered with
tissue Naþ content and mobilization capacity following
transplantation. Previous 23Na-MRI investigations
revealed a sex-dependence and age-correlation of tissue
Naþ storage.7,10 We have also found these correlations
in our cohort pre- and post-transplantation.Kidney International Reports (2021) 6, 2338–2347Furthermore, 2 of 31 CKD patients were diagnosed with
type 2 diabetes mellitus, a condition known to enhance
tissue Naþ accumulation in HD patients.11 Four pa-
tients additionally developed post-transplantation dia-
betes mellitus. A subgroup analysis of these six
patients showed no difference in tissue Naþ amount
after transplantation compared to CKD patients without
diabetes (Supplemental Table S2). To determine further
factors that might be relevant for the observed changes
in tissue Naþ amount following transplantation, we
assessed univariate regression models of tissue Naþ and
clinical as well as laboratory parameters. Besides the
above-mentioned parameters age and sex, excess ECW
(overhydration), blood pressure, and VEGF-C showed a
close association with tissue Naþ (Table 3). Because of
the small number of patients, we were unable to
perform a multivariate analysis to identify effects of
different covariates on Naþ reduction.
We focused on CKD patients who were scheduled for
pre-emptive living-donor kidney transplantation to
avoid interferences of Naþ and water homeostasis by
dialysis treatment as long-term chronic dialysis treat-
ment is associated with various skin pathologies and
thus might affect skin matrix and Naþ deposition.25
Skin biopsy results identified marked differences in
collagen deposition, glycosaminoglycans, and lymph-
angiogenesis between pre-emptive kidney transplant
recipients and chronic dialysis patients.21 None of 31
CKD patients was receiving renal replacement therapy
before the initial 23Na-MRI measurement. Although 28
patients were not dialyzed before kidney trans-
plantation, 3 patients required short-term dialysis
treatment before transplantation. These few patients
revealed a similar pattern of tissue Naþ reduction after
transplantation (Supplemental Table S2).
Although tissue Naþ was markedly mobilized 3 and
6 months after renal transplantation, excess extracel-
lular water (overhydration) as assessed by BIS was not
reduced 3 months after surgery. Six months after
transplantation, a decrease of the initially detected
overhydration was apparent, but not reaching level of
significance. BIS has been widely used in studies on
dialysis patients to determine fluid status more objec-
tively. Even moderate fluid overload was thereby
associated with increased cardiovascular mortality.26,27
In a cohort of 338 CKD patients not on dialysis treat-
ment, hypervolemia was present in more than half of
the study participants, which is comparable to the fluid
status of our CKD cohort.28 In line with our data, a BIS
trial investigating fluid status before and after trans-
plantation revealed a high percentage of persistent
overhydration 3 months after intervention.29 However,
a recent study involving BIS and 23Na-MRI in CKD
patients found that BIS measurements seem to2345
CLINICAL RESEARCH A Dahlmann et al.: Tissue Naþ After Renal Transplantationoverestimate water amount in study participants due to
relying predominantly on tissue Naþ concentration and
its conductance.30 This would be particularly relevant
in light of tissue Naþ deposition, as BIS might rather
reflect Naþ load than water amount and should be kept
in mind when interpreting BIS-derived body water
analysis in our CKD patients.
As previous basic-research and patient-oriented
studies identified the lymphatic system as a consider-
able regulator of tissue Naþ, we further characterized
changes of the lymphangiogenic factors in our study
participants. In animal experiments, NaCl-induced tis-
sue hypertonicity resulted in macrophage-derived
VEGF-C secretion and skin electrolyte drainage.
Disruption of this adaption process by trapping of
VEGF-C with sVEGFR3 leads to hypertonic volume
retention in skin and elevated blood pressure.6,13,14 We
found that an initially reduced VEGF-C concentration
in our CKD patients increased after transplantation,
whereas sVEGFR3 concentration decreased. This
altered pattern in lymphangiogenic factors has already
been described in HD patients, where it was associated
with reduced tissue Naþ mobilization capacity during a
regular 4-hour HD treatment.12 VEGF-C differences
between CKD patients and healthy subjects comparable
to our study have been reported previously,31 whereas
to our knowledge we are the first to describe changes of
these lymphangiogenic factors after transplantation.
However, the association between tissue Naþ and
VEGF-C that occurred in our study does not prove
causality. The observed changes might be due to
multiple other factors such as therapeutic immuno-
suppressants or change of inflammation status.
Furthermore, the kidney itself might be a source of
lymphatic growth factors as in renal ischemia reper-
fusion models VEGF is transiently reduced until renal
function recovers.32 In contrast to the above-mentioned
animal experiments, no histological assessment of
lymph capillary density and hyperplasia were per-
formed in this study. Therefore, we do not know the
direct impact of CKD and subsequent renal trans-
plantation on the lymphatic network.
We are aware of general limitations of our study.Aswe
did not collect data concerning dietary habits during our
study, we do not know its impact on tissue Naþ content
pre- and post-transplantation. However, the analysis of
24-hour urine Naþ excretion did not reveal differences
over 3 time points within the CKD cohort nor in com-
parison to the control group. Besides the mentioned im-
munosuppressants, medication fundamentally changed
after transplantation thereby possibly influencing Naþ
homeostasis. At least no diuretics or sodium-glucose
transport protein 2 inhibitors — both drugs known
to induce tissue Naþ loss—were newly prescribed post2346transplantation (Table 1).33,34 A regression to the mean
cannot be excluded in our data set. Finally, solely
Caucasians were investigated in our study. Thus, re-
sults should not be generalized to all ethnicities, which
is important as for instance African Americans are
known to accumulate higher amounts of tissue Naþ.10
The pathophysiological implications of tissue Naþ
storagemust be further elucidated. Recent data suggest an
association between tissue Naþ accumulation and cardio-
vascular risk. In CKD patients, skin Naþ assessed by 23Na-
MRI was the best predictive factor for left ventricular
hypertrophy, a risk factor for cardiovascular morbidity
and mortality.9 Primary aldosteronism, which causes
myocardial damage independent of blood pressure, was
found to be related not only to muscle and skin tissue Naþ
accumulation but also to increased myocardial Naþ con-
tent.35 Prospective long-term cohort studies must reveal
whether tissue Naþ overload per se is an independent risk
factor for cardiovascular morbidity and mortality.
In summary, we present evidence that tissue Naþ
accumulation occurs in CKD patients and that this over-
load was reduced after renal transplantation almost to the
level of healthy controls. CKD was associated with alter-
ations in lymphangiogenic plasma factors that were
normalized after transplantation, indicating a role of
lymphatic Naþ regulation in CKD. The ultimate relevance
of Naþ accumulation for cardiovascular disease after
transplantation and the role of allograft rejection with
subsequent tissue Naþ retention should be addressed in
further prospective long-term clinical trials.
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